Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
captopril
- Development stage
- Approved
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Captopril is an oral small molecule drug classified as an angiotensin-converting enzyme (ACE) inhibitor. It is primarily used to treat high blood pressure (hypertension), congestive heart failure, and to improve survival and reduce the risk of heart failure after a heart attack in patients with left ventricular dysfunction. Captopril is also indicated for the treatment of diabetic nephropathy in patients with type 1 diabetes and retinopathy. Its mechanism of action involves competitively inhibiting ACE, thereby blocking the conversion of angiotensin I to angiotensin II—a potent vasoconstrictor—resulting in vasodilation, reduced blood pressure, decreased workload on the heart, and renal protection[1][2][3][4][5].
- Brand names
- CapotenCaptoril
- Other names
- captopril
02
Targets
ACE (Angiotensin Converting Enzyme)
Beyond the preview
Go deeper on captopril.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on captopril.